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Abstract
Background: Combination of erlotinib and bevacizumab is a promising regimen in advanced non-squamous non-
small-cell lung cancer (NSCLC). We are conducting a single arm phase II trial which aims to evaluate the efficacy
and safety of this regime as a second- or third-line chemotherapy.
Methods: Key eligibility criteria were histologically or cytologically confirmed non-squamous NSCLC, stage III/IV or
recurrent NSCLC not indicated radical chemoradiation, prior one or two regimen of chemotherapy, age 20 years or
more, and performance status of two or less. The primary endpoint is objective response rate. The secondary
endpoints include overall survival, progression-free survival, disease control rate and incidence of adverse events.
This trial plans to accrue 80 patients based on a two-stage design employing a binomial distribution with an
alternative hypothesis response rate of 35% and a null hypothesis threshold response rate of 20%. A subset analysis
according to EGFR mutation status is planned.
Discussion: We have presented the design of a single arm phase II trial to evaluate the efficacy and safety of
combination of bevacizumab and erlotinib in advanced non-squamous NSCLC patients. In particular we are
interested in determining the merit of further development of this regimen and whether prospective patient
selection using EGFR gene is necessary in future trials.
Trial registration: This trial was registered at the UMIN Clinical Trials Registry as UMIN000004255 (http://www.
umin.ac.jp/ctr/index.htm).
Background
Chemotherapy for advanced non-small-cell lung cancer
(NSCLC) patients with good performance status
improves survival time and quality of life [1]. Platinum
doublet therapies with third-generation agents are
thought as the standard in first-line for NSCLC patients,
of which response rate is 30-40%, one year survival rate is
26-36% and median survival time is 8-13 months [2-4].
For patients who had relapsed or did not respond to
first-line chemotherapy, docetaxel [5-7] and pemetrexed
[8] are effective. Erlotinib, an oral epidermal growth
factor receptor tyrosine kinase inhibitor (EGFR-TKI), was
also shown to improve progression-free survival (PFS)
and overall survival (OS) modestly with acceptable toxi-
city in second- or third-line setting for advanced NSCLC
[9,10]. On third-line treatment only erlotinib is recom-
mended by the National Comprehensive Cancer Network
guideline [11] and no established treatment options exist
for patients who have experienced erlotinib failure.
Several lines of evidence lent support to the notion that
combining bevacizumab, a monoclonal antibody targeting
the vascular endothelial growth factor (VEGF), with erloti-
nib for advanced NSCLC might confer additional clinical
benefit. Two large phase III trials confirmed that bevacizu-
mab improves survival of advanced non-squamous
NSCLC patients when combined with carboplatin plus
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any medium, provided the original work is properly cited.paclitaxel or cisplatin plus gemcitabine as first-line che-
motherapy [12,13]. A significant improvement in PFS and
objective response rate (ORR) by the addition of bevacizu-
mab with carboplatin plus paclitaxel was also shown in a
randomize phase II trial of Japanese patients [14]. Finally,
a recent randomized phase II trial of combination of beva-
cizumab with erlotinib, combination with cytotoxic drug,
and cytotoxic drugalone showed results for PFS and OS
favour the combination regimens over cytotoxic drug
alone in the second-line setting, although not statistically
significant [15].
Objective
The primary objective of the trial is to evaluate the efficacy
and safety of combination of bevacizumab and erlotinib as
a second- or third-line chemotherapy for advanced non-
squamous NSCLC. Specific hypotheses to be tested are (1)
one-sided hypothesis that the ORR of combination of beva-
cizumab and erlotinib is higher than a pre-specified thresh-
old of 20%, (2) whether this regimen are safe and feasible,
and (3) whether the ORR is higher in patients with EGFR
mutation than in patients with EGFR wild type.
Methods
Design and setting
This study is an open-label, multi-institute, single arm
phase II clinical trial. The coordinating office is at Kyoto
University Hospital. Registration and data collection are
conducted with the use of the web system and the elec-
tronic case report form (e-CRF).
Ethical consideration and registration
The study protocol is according to the Helsinki declara-
tion [16] and the Ethics Guidelines for Clinical Research
by the Ministry of Health, Labor, and Welfare [17]. We
obtained approval by the ethical committee at Kyoto
University on October 27, 2010 (C-453). This trial was
registered at the UMIN Clinical Trials Registry as
UMIN000004255 (http://www.umin.ac.jp/ctr/index.htm).
Eligibility criteria
Staging was according to the 7th Edition of the TNM
Classification for Lung Cancer [18]. Inclusion criteria
are as follows:
1) Histologically or cytologically confirmed non-squa-
mous NSCLC.
2) Stage III/IV or recurrent NSCLC not indicated
radical chemoradiation, and prior one or two regimen of
chemotherapy.
3 )A g e2 0y e a r so rm o r ea tt h ed a t eo fi n f o r m e d
consent.
4) The Eastern Cooperative Oncology Group Perfor-
mance Status of two or less.
5) Presence of measurable lesion.
6) Sufficient hematologic, hepatic, and renal and lung
function in laboratory tests 14 days before registration.
7) Expected survival time more than three months.
8) Expected interval more than 28 days after surgery if
the patient received a major surgery.
9) Written informed consent by the patient.
Exclusion criteria are as follows:
1) Prior EGFR-TKI.
2) Serious complications.
3) Hemoptysis or bloody sputum of 2.5 mL or more,
or history of clinically significant hematemesis, coagula-
tion disorder or thrombosis.
4) A cavitating lesion, a central lesion or a lesion abut-
ting major blood vessels.
5) History of myocardial or cerebral infarction within
six months before registration.
6) Refusal of contraception or woman with on-going
or contemplating pregnancy or breast-feeding.
7) Brain metastasis with a bleeding risk.
8) Interstitial pneumonia confirmed by computer
tomography.
9) Difficulty in ingestion.
10) Pleural effusion which is uncontrolled by local
therapy and requires other treatments
11) Patients judged inappropriate for the trial by
investigators.
Patient registration
After confirming eligibility criteria and obtaining
informed consent. Eligible patients are registered and
then investigators initiate the planned treatment. The
accrual started in November 2010 and is to continue for
two years.
Treatment
Patients enrolled in this trial receive the protocol treat-
ment with bevacizumab and erlotinib within 15 days.
Dose of the protocol treatment is based on the prior
trials [15,19]. Bevacizumab is administered at a dose of
15 mg/kg on the first day of each 3-week cycle. No dose
reductions are allowed for bevacizumab. Bevacizumab is
terminated if either of the following adverse events
occurs.
1) Grade 2 to 4 hemorrhage
2) Grade 3 to 4 thrombosis
3) Delay of administration of each cycle over 23 days
Erlotinib is administered initially at 150 mg/day orally.
Tablets are taken at least one hour before or two hours
after a meal, preferably in the morning. Dose of erlotinib
are reduced by one or two levels of five doses, 150, 125,
100, 75 and 50 mg, if either of the following adverse events
occurs.
1) Unacceptable skin toxicity
2) An increase in AST or ALT up to Grade 3 to 4
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Dose escalations for erlotinib are not allowed after a
dose reduction. Erlotinib is terminated if either of the
following adverse events occurs.
1) Grade 1 to 4 pulmonary fibrosis
2) Grade 4 non-hematologic toxicity other than pul-
monary fibrosis
3) Delay from prior administration over 23 days
The protocol treatment is terminated if the disease
progresses, serious adverse events occurs or at the
patient’s refusal. There is no restriction of maximum
number of cycles. There is no restriction of treatment
after failure of the protocol treatment.
Endpoints
The primary endpoint is ORR. The secondary endpoints
are PFS, OS, disease control rate (DCR) and incidence of
adverse events. Patients undergo tumor assessments at
baseline and every six weeks by investigators using
Response Evaluation Criteria in Solid Tumors version 1.1
[20]. ORR and DCR are defined by the proportion of com-
plete response (CR) and partial response (PR), or the pro-
portion of CR, PR and stable disease (SD), in confirmed
best overall response at the time of the primary analysis.
OS is defined as the time from registration to death from
any cause, and it is censored at the last contact date for
living patient. PFS is defined as the time from registration
to either the first event of progression of disease or death
from any cause, and it is censored at the last date when
patient is alive without progression. Adverse events are
evaluated according to the Common Terminology Criteria
for Adverse Events (CTCAE) version 4.0 [21].
Data collection
Patients are followed-up for three months after registra-
tion. Schedule of data collection are summarised in
Table 1. Radiographic data for tumor assessments is col-
lected every six weeks.
Sample size determination
Simon’s minimax two-stage design employing a bino-
mial distribution is used to calculate the required sam-
p l es i z e .I nt h ep r e v i o u st r i a l s ,t h eO R Ro fe r l o t i n i b
monotherapy ranged 8.9 to 28.3% [9,10]. Thus we con-
sider that an ORR of 20% indicates no value of further
investigation of the combination. This trial plans to
accrue 42 patients in the first stage and 80 patients in
total, which provides 90% power with an alternative
hypothesis ORR of 35% and a null hypothesis ORR of
20% using one-sided testing at a 5% significance level.
Statistical consideration
The analysis population for efficacy is the full analysis set.
The primary analysis for efficacy is a one-sided binomial
test with the null hypothesis of 20% at a 5% significance
level in the second stage. A subset analysis according to
EGFR mutation status (direct sequence or PNA-LNA PCR
clamp methods) is also planned. ORRs with 95% confi-
dence intervals are calculated in the subsets of mutant and
wild type, and compared with 20% using the same
Table 1 Schedule of data collection
Baseline Under
treatment
At termination
of treatment
After termination
of treatment
Physical examination
Height ○
Weight, performance status ○○ ○
Blood pressure ○○ ○ ○
Laboratory test
Blood count ○○
Biochemistry test ○○
Urine test ○○
SpO2 ○○ ○
*1
Electrocardiography ○○
*1
EGFR gene ○
Radiology test
Chest Xp ○○
*1 ○
*1
Chest CT ○○
*2 ○
*3
Abdominal CT/Ultra sonography ○○
*2 ○
*3
Head CT/MRI ○○
*1 ○
*1
Bone scintigraphy/PET ○○
*1 ○
*1
*1 If necessary
*2 Every 6 weeks
*3 Six weeks after termination if treatment is terminated for reasons other than progression of disease
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city is not adjusted for since this is a secondary analysis.
Discussion
We have presented the design of a single arm phase II
trial to evaluate the efficacy and safety of combination
of bevacizumab and erlotinib in advanced non-squa-
mous NSCLC patients. In particular we are interested in
determining the merit of further development of this
regimen and whether prospective patient selection using
EGFR gene is necessary in future trials.
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